Skyline Corporate Communications Group, LLC President, Scott Powell, Named by Business Insider Magazine as one of the Nation’s Top 18 Public Relations Executives
September 27, 2023 08:00 ET
|
Skyline Corporate Communications Group, LLC
New York, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Skyline Corporate Communications Group, LLC, a consulting agency that provides customized corporate communications and strategic investor relations...
Ohmyhome Ltd. Retains Skyline Corporate Communications Group, LLC to Provide Investor Relations Services
June 27, 2023 09:45 ET
|
Ohmyhome Ltd.
SINGAPORE, June 27, 2023 (GLOBE NEWSWIRE) -- Ohmyhome Limited (“Ohmyhome” or the Company) (NASDAQ: OMH), a data-driven property technology company based in Singapore, today announced it has retained...
Castellum, Inc. Retains Skyline Corporate Communications Group, LLC to Provide Investor Relations Services
November 04, 2022 06:55 ET
|
Castellum, Inc.
POTOMAC, Md., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Castellum, Inc. (“Castellum” or the “Company”) (NYSE American: CTM), a cybersecurity, electronic warfare, data analytics, software, and IT services...
Vyant Bio to Present at the H.C. Wainwright 24th Annual Global Investment Conference
August 31, 2022 08:00 ET
|
Vyant Bio, Inc.
CHERRY HILL, N.J., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex...
Vyant Bio Postpones Second Quarter Investor Conference Call and Webcast
August 15, 2022 08:05 ET
|
Vyant Bio, Inc.
CHERRY HILL, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex...
Vyant Bio Retains Skyline Corporate Communications Group, LLC to Provide Investor Relations Services
June 01, 2022 18:05 ET
|
Vyant Bio, Inc.
CHERRY HILL, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex...